Yesterday, at the British Society for Rheumatology’s Annual Conference held in Liverpool, United Kingdom, researchers presented a study that investigated the clinical outcomes of a multi-disciplinary switch to biosimilar etanercept from the reference product in patients with rheumatoid arthritis.
Yesterday, at the British Society for Rheumatology’s Annual Conference held in Liverpool, United Kingdom, researchers presented a study that investigated the clinical outcomes of a multi-disciplinary switch to biosimilar etanercept from the reference product in patients with rheumatoid arthritis (RA).
Developed by drug manufacturer Samsung Bioepis, the biosimilar etanercept (sold as Benepali in the European Union) is licensed to treat RA, psoriatic arthritis, and psoriasis. The drug has been approved in the European Union since January 1, 2016.
Researchers noted that there are limited study data available on switching patients with RA from the originator product to biosimilar etanercept with regard to clinical efficacy, tolerability, and safety. The study investigated these criteria in addition to evaluating patient perspectives on switching to a biosimilar.
The study enlisted 151 patients with RA, and enrollees were offered an education session as well as a dedicated biosimilar switching clinic staffed by a rheumatology consultant, a registrar, and specialty pharmacist both before the switch and 4 months after the switch.
During the 2 assessments, a disease activity score in 28 joints (DAS-28) was evaluated in addition to each patient completing a health assessment questionnaire (HAQ), European Quality of Life-5 Dimensions questionnaire (EQ-5D), and an 11-part biosimilars questionnaire that asked about tolerability and adverse events related to the biosimilar.
The patients were switched from the reference etanercept to the biosimilar between January 2017 and June 2017. Researchers found that the switch would result in a cost savings of approximately $675,902 (£500,000) per year based on the drugs’ prices during the time the study was conducted.
The researchers also found that, in a relatively short period of time, a large number of patients with RA were able to safely switch to the biosimilar etanercept in a controlled setting with the 114 patients achieving a mean DAS-28 score of 2.66 with the etanercept biosimilar versus a mean score of 2.97 with the originator etanercept (P =.0019).
In total, 8 patients were switched back to the reference product. This was due to 5 patients experiencing adverse events (rash and diarrhea were reported), and 3 patients having difficulty using the auto-injector pen. Two patients experienced disease flares.
When asked how they felt about their RA disesase control after the switch, 75% of patients said they felt no different. Furthermore, when 113 patients were asked how pleased they were with the switch, 50 (43%) reported they were pleased, 8 (7%) reported they were indifferent, 9 (8%) reported they weren’t sure, 27 (23%) reported they were not pleased. (The remaining patients did not answer the question.)
In addition, the method of delivery of the biosimilar was preferred by most patients, who commented on the easier technique and reduced manual dexterity required to administer the drug.
The researchers concluded by stating that the positive results of this switching study should encourage physicians and patients to switch to a biosimilar in order to optimize cost savings.
Reference
Shah K, Flora K, Penn H. Clinical outcomes of a multi-disciplinary switching program to biosimilar etanercept for patients with rheumatoid arthritis. Abstract presented at The British Society for Rheumatology’s Annual Conference; May 1-3, 2018; Liverpool, United Kingdom. Abstract 232. abstractsonline.com/pp8/#!/4506/presentation/1539.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.